Press Release

     View printer-friendly version
    << Back
    Blueprint Medicines Announces Data Presentations at Upcoming ASCO and EHA Meetings Supporting Plans for Rapid Development of Avapritinib in Patients with Gastrointestinal Stromal Tumors and Systemic Mastocytosis

    CAMBRIDGE, Mass., May 17, 2018 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced two data presentations supporting plans for rapid development of avapritinib, a selective KIT and PDGFRα inhibitor, in patients with gastrointestinal stromal tumors (GIST) and systemic mastocytosis (SM).

    Print

    Data from a retrospective natural history study of previously treated patients with advanced PDPGFRα D842V-driven GIST will be presented in a poster session at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois on June 1-5, 2018. In addition, updated data from Blueprint Medicines' Phase 1 EXPLORER trial of avapritinib in patients with advanced SM will be presented in a poster session at the 23rd Congress of the European Hematology Association (EHA) in Stockholm, Sweden on June 14-17, 2018. 

    The accepted abstracts are listed below and are now available online on the ASCO and EHA conference websites, respectively: https://am.asco.org/ and https://ehaweb.org/congress/23rd-c/key-information/

    2018 American Society of Clinical Oncology (ASCO) Annual Meeting

    Presentation Title: A retrospective natural history study of patients (pts) with PDGFRα D842V mutant advances gastrointestinal stromal tumor (GIST) previously treated with a tyrosine kinase inhibitor (TKI)
    Session Title: Sarcoma
    Session Date & Time: Saturday, June 2, 2018 from 8:00 a.m.11:30 a.m. CT (9:00 a.m.12:30 p.m. ET)
    Abstract Number: 11533
    Poster Board Number: 278
    Location: Hall A, McCormick Place

    23rd Congress of the European Hematology Association (EHA)

    Presentation Title: Avapritinib (BLU-285), a Selective KIT Inhibitor, is Associated with High Response Rate and Tolerable Safety Profile in Advanced Systemic Mastocytosis (AdvSM): Results of a Phase 1 Study 
    Session Title: Myeloproliferative neoplasms - Clinical
    Session Date & Time: Friday, June 15, 2018 from 17:30 – 19:00 CEST (11:30 a.m.1:00 p.m. ET)
    Abstract Number: PF612
    Location: Poster Area, Stockholmsmässan

    About Blueprint Medicines

    Blueprint Medicines is developing a new generation of targeted and potent kinase medicines to improve the lives of patients with genomically defined diseases. Its approach is rooted in a deep understanding of the genetic blueprint of cancer and other disease driven by the abnormal activation of kinases. Blueprint Medicines is advancing multiple programs in clinical development for subsets of patients with gastrointestinal stromal tumors, hepatocellular carcinoma, systemic mastocytosis, non-small cell lung cancer, medullary thyroid cancer and other advanced solid tumors, as well as multiple programs in research and preclinical development. For more information, please visit www.blueprintmedicines.com.

    Cision View original content with multimedia:http://www.prnewswire.com/news-releases/blueprint-medicines-announces-data-presentations-at-upcoming-asco-and-eha-meetings-supporting-plans-for-rapid-development-of-avapritinib-in-patients-with-gastrointestinal-stromal-tumors-and-systemic-mastocytosis-300650273.html

    SOURCE Blueprint Medicines

    Investor and Media Relations Contacts: Kristin Hodous, 617-714-6674, KHodous@blueprintmedicines.com; Jim Baker, 617-844-8236, JBaker@blueprintmedicines.com



    Print Page  | E-mail Page  | RSS Feeds  | E-mail Alerts  | Financial Tear Sheet